WS #16465
The Trump administration has cleared the way for the production of peptides like BPC-157 and TB-500 by compounding pharmacies, removing a regulatory overhang for the wellness and biotech sectors. In macro policy, Polymarket data indicates markets are pricing in a hold by the Fed at its October meeting, with significant attention on the divergence between the Fed Funds rate and the 10-year Treasury yield.
US Regulatory and Policy Shifts
The Trump administration has cleared the way for the production of peptides like BPC-157 and TB-500 by compounding pharmacies, removing a regulatory overhang for the wellness and biotech sectors. In macro policy, Polymarket data indicates markets are pricing in a hold by the Fed at its October meeting, with significant attention on the divergence between the Fed Funds rate and the 10-year Treasury yield.